BSAM
FRTX

Blue Square Asset Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Blue Square Asset Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-418
Closed -$19K – 186
2020
Q2 		$19K Buy
+418
New +$22.3K 0.01% 152

Other funds holding FRTX

PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSWM
Smith Salley Wealth Management Greensboro, North Carolina $2.3B AUM 38.65% 1-Year Est. Return

Blue Square Asset Management's FRTX Position: Q3 2020 in Review

Blue Square Asset Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2020, closing a stake of 418 shares — an estimated $19K sold.

Blue Square Asset Management first reported a position in FRTX in Q2 2020 and held it in 1 quarter. The position peaked at $19K in Q2 2020. 17 funds tracked by Wall St. Rank hold FRTX as of Q3 2020.

  • Blue Square Asset Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Blue Square Asset Management sold 418 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $19K.
  • Blue Square Asset Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Blue Square Asset Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $19K in Q2 2020.
  • 17 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Blue Square Asset Management's 13F filing for Q3 2020, filed 10 Nov 2020.